Survivin, a member of the Inhibitors of Apoptosis (IAP) family, is either undetectable or expressed at very low levels in terminally differentiated normal human tissues, but it is highly expressed in all primary tumor types3–7, making it an ideal target for cancer therapy. Here, BIRC5 is linked to cancer.